MELINDA VANKOOTEN: Open Payments
NPI 1730814930 · KEARNEY, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$475 in 13 payments from 9 companies in 2025. Trend: 2023 $154 · 2024 $17 · 2025 $475
Food & beverage: $475
| Company | Payments | Amount |
|---|---|---|
| Travere Therapeutics, Inc. | 4 | $179 |
| Novo Nordisk Inc | 1 | $124 |
| GlaxoSmithKline, LLC. | 2 | $36 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $33 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $27 |
| ABBVIE INC. | 1 | $24 |
| Fresenius USA Marketing, Inc. | 1 | $19 |
| GENZYME CORPORATION | 1 | $17 |
| Mallinckrodt Hospital Products Inc. | 1 | $16 |
Products named: Filspari, Ozempic, SHINGRIX, EOHILIA, Kerendia, MAVYRET, VELPHORO, DUPIXENT.
Industry payments across NE — which companies pay providers there.
